Suppression of the release of type-1 plasminogen activator inhibitor from human vascular endothelial cells by Hawaii deep sea water

Pathophysiology

Volumn 9, Issue 2, 2003, Pages 103-109

  Ueshima, Shigeru ^a   Fukao, Hideharu ^a   Okada, Kiyotaka ^a   Matsuo, Osamu ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Deep sea water; Endothelial cells; Fibrinolytic activity; Tissue type plasminogen activator; Type 1 plasminogen activator inhibitor

Indexed keywords

ANTICOAGULANT AGENT; FIBRIN; IODINE 125; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ARTICLE; BLOOD CLOT LYSIS; CELL CULTURE; CONTROLLED STUDY; DEEP SEA; DRUG ELIMINATION; DRUG RELEASE; ENDOTHELIUM CELL; FIBRIN CLOT; FIBRINOLYSIS; GROWTH RATE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REDUCTION; THROMBOSIS; UMBILICAL VEIN; UNITED STATES; VASCULAR ENDOTHELIUM;

EID: 0142029524     PISSN: 09284680     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-4680(02)00076-7     Document Type: Article

References (15)

1. Sprengers E.D. Plasminogen activator inhibitors. Blood. 69:1987;381-387.
2. Matsuo O. New thrombolytic agents: Basic development. Yamaguchi T., Morie E., Minematsu K., del Zoppo G.J. Thrombolytic Therapy in Acute Ischemic Stroke III. 1995;182-187 Springer, Tokyo.
3. Husain S.S., Gurewich V., Lipinski B. Purification and partial characterization of a single-chain high-molecular-weight form of urokinase from human urine. Arch. Biochem. Biophys. 220:1983;31-38.
4. Matsuo O., Rijken D.C., Collen D. Thrombolysis by human tissue plasminogen activator and urokinase in rabbits with experimental pulmonary embolus. Nature. 291:1981;590-591.
5. Collen D. On the regulation and control of fibrinolysis. Edward Kowalski Memorial Lecture. Thromb. Haemost. 43:1980;77-89.
6. Colman R.W., Marder V.J., Salzman E.W., Hirsh J. Overview of hemostasis. Colman R.W., Hirsh J., Marder V.J., Salzman E.W. Haemostasis and Thrombolysis. Basic Principles and Clinical Practice. third ed. 1993;3-17 JP Lippincott, Philadelphia.
7. Holmes W.E., Nelles L., Lijnen H.R., Collen D. Primary structure of human alpha 2-antiplasmin, a serine protease inhibitor (serpin). J. Biol. Chem. 262:1987;1659-1664.
8. Folsom A.R., Aleksic N., Park E., Salomaa V., Juneja H., Wu K.K. Prospective study of fibrinolytic factors and incident coronary heart disease; the Atherosclerosis Risk in Communities (ARIC) Study. Thromb. Vasc. Biol. 21:2001;611-617.
9. Rerolle J.P., Vigneau C., Hertig A., Berrou J., Rondeau E. Plasminogen activator inhibitor type 1: physiology and role in renal physiopathology. Nephrologie. 22:2001;5-13.
10. Pedersen H., Brunner N., Francis D., Osterlind K., Ronne E., Hansen H.H., Dano K., Grondahl-Hansen J. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res. 54:1994;4671-4675.
11. Schleef R.R., Bevilacqua M.P., Sawdey M., Gimbrone M.A. Jr., Loskutoff D.J. Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. J. Biol. Chem. 263:1988;5759-5803.
12. Fukao H., Ueshima S., Okada K., Yamamoto K., Matsuo T., Matsuo O. Tissue-type plasminogen activator, type 1 plasminogen activator inhibitor and their complex in plasma with disseminated intravascular coagulation. Thromb. Res. 68:1992;57-65.
13. Estelles A., Dalmau J., Falco C., Berbel O., Castello R., Espana F., Aznar J. Plasma PAI-1 levels in obese children - effect of weight loss and influence of PAI-1 promoter 4G/5G genotype. Thromb. Haemost. 86:2001;647-652.
14. Fukao H., Ueshima S., Okada K., Matsuo O. The role of the pericellular fibrinolytic system in angiogenesis. Jpn J. Physiol. 47:1997;161-171.
15. Goldsack N.R., Chambers R.C., Dabbagh K., Laurent G.J. Thrombin. Int. J. Biochem. Cell. Biol. 30:1998;641-646.